J
Jennifer S. Y. Ma
Researcher at Torrey Pines Institute for Molecular Studies
Publications - 14
Citations - 1136
Jennifer S. Y. Ma is an academic researcher from Torrey Pines Institute for Molecular Studies. The author has contributed to research in topics: Cytotoxic T cell & Chimeric antigen receptor. The author has an hindex of 12, co-authored 14 publications receiving 907 citations. Previous affiliations of Jennifer S. Y. Ma include Children's National Medical Center.
Papers
More filters
Journal ArticleDOI
Switch-mediated activation and retargeting of CAR-T cells for B-cell malignancies
David T. Rodgers,Magdalena Mazagova,Eric Hampton,Yu Cao,Nitya S. Ramadoss,Ian R. Hardy,Andrew D Schulman,Juanjuan Du,Feng Wang,Oded Singer,Jennifer S. Y. Ma,Vanessa Núñez,Jiayin Shen,Ashley K. Woods,Timothy M. Wright,Peter G. Schultz,Chan Hyuk Kim,Travis S. Young +17 more
TL;DR: It is shown that switches specific for CD19 govern the activity, tissue-homing, cytokine release, and phenotype of switchable CAR-T cells in a dose-titratable manner using xenograft mouse models of B-cell leukemia.
Journal ArticleDOI
Versatile strategy for controlling the specificity and activity of engineered T cells.
Jennifer S. Y. Ma,Ji Young Kim,Stephanie A. Kazane,Sei-hyun Choi,Hwayoung Yun,Min Soo Kim,David T. Rodgers,Holly Pugh,Oded Singer,Sophie B. Sun,Bryan R. Fonslow,James N. Kochenderfer,Timothy M. Wright,Peter G. Schultz,Travis S. Young,Chan Hyuk Kim,Yu Cao +16 more
TL;DR: It is demonstrated that a switch-mediated CAR-T approach enables the titration of engineered T-cell antitumor activity, which was observed to be highly advantageous in reducing treatment-related toxicities in vivo.
Journal ArticleDOI
Redirection of genetically engineered CAR-T cells using bifunctional small molecules.
Min Soo Kim,Jennifer S. Y. Ma,Hwayoung Yun,Yu Cao,Ji Young Kim,Victor Chi,Danling Wang,Ashley K. Woods,Lance Sherwood,Dawna Caballero,Jose Gonzalez,Peter G. Schultz,Peter G. Schultz,Travis S. Young,Chan Hyuk Kim +14 more
TL;DR: It is demonstrated that a bifunctional small molecule "switch" consisting of folate conjugated to fluorescein isothiocyanate (folate-FITC) can redirect and regulate FITC-specific CAR-T cell activity toward folate receptor (FR)-overexpressing tumor cells.
Journal ArticleDOI
Design of Switchable Chimeric Antigen Receptor T Cells Targeting Breast Cancer.
Yu Cao,David T. Rodgers,Juanjuan Du,Insha Ahmad,Eric Hampton,Jennifer S. Y. Ma,Magdalena Mazagova,Sei-hyun Choi,Hwayoung Yun,Han Xiao,Peng-Yu Yang,Xiaozhou Luo,Reyna K. V. Lim,Holly M. Pugh,Feng Wang,Stephanie A. Kazane,Timothy M. Wright,Chan Hyuk Kim,Chan Hyuk Kim,Peter G. Schultz,Peter G. Schultz,Travis S. Young +21 more
TL;DR: A switchable CAR-T cell platform in which the activity of the engineered cell is controlled by dosage of an antibody-based switch is developed, which may facilitate the application of immunotherapy to solid tumors by affording comparable efficacy with improved safety owing to switch-based control of theCAR-T response.
Journal ArticleDOI
Targeting Human C‐Type Lectin‐like Molecule‐1 (CLL1) with a Bispecific Antibody for Immunotherapy of Acute Myeloid Leukemia
Hua Lu,Quan Zhou,V. Deshmukh,Hardeep Phull,Jennifer S. Y. Ma,Virginie Tardif,Rahul R. Naik,Claire Bouvard,Yong Zhang,Sei-hyun Choi,Brian R. Lawson,Shoutian Zhu,Chan Hyuk Kim,Peter G. Schultz,Peter G. Schultz +14 more
TL;DR: The synthesis of a novel bispecific antibody, αCLL1-αCD3, is described, using the genetically encoded unnatural amino acid, p-acetylphenylalanine, which demonstrates potent and selective cytotoxicity against several human AML cell lines and primary AML patient derived cells in vitro.